Potassium Iodate (KIO3) — Manufacturer & Supplier | Thyroid Stockpile Supply
Golden Hour Pharma is your single-point-of-contact for pharmaceutical-grade Potassium Iodate supply — engineered for national stockpile programmes, emergency preparedness frameworks, and institutional thyroid protection protocols.
Request a QuotationWhat Is Potassium Iodate?
Potassium Iodate (KIO3) is an inorganic compound (molecular formula KIO3) used as a stable-iodine thyroid-blocking agent in nuclear and radiological emergencies, and as the principal iodine source in many national salt-fortification programmes. KIO3 is preferred over Potassium Iodide (KI) in tropical and high-humidity regions because it does not oxidise or degrade under heat and moisture, giving it a shelf-life advantage for long-term national stockpile programmes. For radiation protection, the adult dosage is 170 mg (equivalent in stable-iodine content to 130 mg of KI), saturating the thyroid gland and blocking uptake of radioactive iodine-131. Pharmaceutical-grade KIO3 is supplied as scored tablets (85 mg, 170 mg) and bulk powder, manufactured under WHO-GMP and compliant with USP, BP, and IP pharmacopoeia standards. The World Health Organization lists KIO3 alongside KI for emergency thyroid blocking in its radiological guidance.
Chemical Identity
Potassium Iodate (KIO3) is an inorganic compound with the molecular formula KIO3. It is a stable, white crystalline powder that serves as a reliable source of iodine in pharmaceutical applications. Unlike Potassium Iodide (KI), KIO3 demonstrates superior chemical stability — particularly in tropical and high-humidity environments — making it the preferred thyroid blocking agent for long-term national stockpile programmes in many regions.
Pharmaceutical Form
Golden Hour Pharma supplies KIO3 in scored tablet form at standard strengths (170 mg and 85 mg), as well as bulk pharmaceutical-grade powder for government and institutional programmes requiring custom formulations. All tablets are manufactured in WHO-GMP certified facilities.
Thyroid Blocking Mechanism
During a nuclear or radiological emergency, radioactive iodine (I-131) can be released into the environment. The thyroid gland readily absorbs iodine — and if radioactive iodine reaches the thyroid, it significantly increases the risk of thyroid cancer and other disorders. KIO3 works by saturating the thyroid with stable iodine before exposure, effectively blocking the uptake of radioactive isotopes. When administered within the recommended window, thyroid blocking can reduce I-131 absorption by over 95%.
Role in National Stockpiles
Numerous countries — particularly across Africa, MENA, and South-East Asia — maintain or are developing national stockpiles of thyroid blocking agents as part of their radiation emergency preparedness frameworks. KIO3 is frequently selected for these programmes due to its extended shelf life and stability under variable storage conditions, as recognised in WHO and IAEA guidance documents.
KIO3 vs KI: Key Differences
| Factor | Potassium Iodate (KIO3) | Potassium Iodide (KI) |
|---|---|---|
| Chemical Stability | High — resistant to oxidation and humidity | Lower — hygroscopic, degrades in heat and humidity |
| Shelf Life (stockpile) | Longer under variable storage | Shorter without climate-controlled storage |
| WHO Position | Accepted thyroid blocking agent | Accepted thyroid blocking agent |
| Tropical Suitability | Preferred in tropical / humid climates | May require additional packaging protection |
| Iodine Content per mg | ~59% iodine by weight | ~76% iodine by weight |
| Dose Equivalence | 170 mg KIO3 = approx. 130 mg KI | 130 mg standard adult dose |
Both KIO3 and KI are effective thyroid blocking agents recognised by the WHO and IAEA for use in radiation emergencies. The primary advantage of Potassium Iodate lies in its superior chemical stability — it does not degrade as readily in high-temperature or high-humidity environments, making it the practical choice for stockpile programmes in tropical and subtropical regions. The WHO has confirmed that both agents are acceptable for thyroid prophylaxis, and the choice between them often comes down to storage infrastructure and programme-specific requirements.
Golden Hour Pharma supplies both KIO3 and KI. View our Potassium Iodide (KI) product page for detailed KI specifications.
Available Specifications
| Grade | Strength | Form | Packaging |
|---|---|---|---|
| Pharmaceutical (WHO-GMP) | 170 mg | Tablets (scored) | Blister packs / HDPE bottles — 10, 14, 30, 100 count |
| Pharmaceutical (WHO-GMP) | 85 mg | Tablets (scored, paediatric dosing) | Blister packs / HDPE bottles — 10, 14, 30, 100 count |
| Pharmaceutical (BP/USP) | Custom strengths | Tablets / Powder | Bulk drums (25 kg) or custom institutional packaging |
Custom strengths, formulations, and packaging configurations are available for institutional and government orders. Contact us to discuss your specific requirements.
Quality & Compliance
WHO-GMP Certified
All KIO3 products are manufactured in WHO-GMP approved facilities meeting international pharmaceutical standards.
Batch Validation
Every production batch undergoes rigorous analytical testing, dissolution studies, and stability validation before release.
Certificate of Analysis
Full Certificates of Analysis (CoA) are provided with every shipment, documenting assay, purity, dissolution, and impurity profiles.
Pharmacopoeial Compliance
Products manufactured to BP, USP, and IP specifications, with regulatory dossiers available for national authority registration.
Procurement Process
Requirement Consultation
Share your programme specifications — volume, strength, packaging, regulatory requirements, and delivery timeline.
Technical Proposal & Documentation
Receive a detailed proposal with product specifications, Certificates of Analysis (CoA), WHO-GMP documentation, and pricing.
Batch Production & Validation
Your order is manufactured under WHO-GMP conditions with full batch validation, stability testing, and quality release.
Delivery & Ongoing Support
Temperature-controlled logistics with complete shipment documentation. Ongoing support for restocking, shelf-life management, and regulatory queries.
Frequently Asked Questions
What is the difference between Potassium Iodate (KIO3) and Potassium Iodide (KI)?
Both KIO3 and KI are stable iodine compounds used for thyroid blocking during nuclear or radiological emergencies. KIO3 is preferred for long-term stockpile programmes in tropical and high-humidity regions because it does not oxidise or degrade under heat and moisture, whereas KI offers a faster onset of thyroid protection and is the default agent in FDA and CDC protocols. The equivalent adult dose is 170 mg of KIO3 versus 130 mg of KI (matched on stable-iodine content). Learn more about Potassium Iodide (KI)
Why do national stockpile programmes choose Potassium Iodate over Potassium Iodide?
KIO3 has superior chemical stability under heat and humidity, giving it a longer shelf life in warehouses and field conditions typical of tropical and sub-tropical regions. For national stockpile programmes requiring multi-year inventory with minimal climate-controlled storage, KIO3 reduces replacement frequency and supply-chain cost. The World Health Organization lists KIO3 alongside KI in its radiological emergency guidance.
What pharmacopoeia grades of Potassium Iodate do you supply?
Golden Hour Pharma supplies Potassium Iodate in WHO-GMP certified pharmaceutical grade, with tablets and bulk powder available to USP, BP, and IP pharmacopoeia specifications. Custom-grade formulations can be developed for specific ministry or institutional requirements. All batches ship with Certificates of Analysis, stability data, and complete regulatory documentation.
What is the shelf life of Potassium Iodate tablets?
Pharmaceutical-grade KIO3 tablets from Golden Hour Pharma carry a minimum 5-year shelf life from date of manufacture, stored under recommended conditions (below 25 degrees Celsius, protected from light and moisture). Extended stability and re-certification programmes are available for national stockpile frameworks requiring longer validated storage windows.
Can Golden Hour Pharma supply KIO3 in bulk for government stockpile programmes?
Yes. Golden Hour Pharma supports national stockpile, ministry, and defence procurement programmes across Africa, MENA, and Latin America with bulk KIO3 supply — tablets at 85 mg and 170 mg, plus bulk pharmaceutical-grade powder for institutional formulation. Custom labelling, packaging configurations, and coordinated logistics are available for large-volume institutional orders.
Is Potassium Iodate safe for thyroid protection during a nuclear emergency?
Yes, when administered at the correct adult dose (170 mg KIO3) within the protective window around radioiodine exposure, KIO3 saturates the thyroid with stable iodine and blocks uptake of radioactive iodine-131. KIO3 is approved by the World Health Organization and used in national emergency protocols worldwide. As with any pharmaceutical, individuals with iodine hypersensitivity, specific thyroid conditions, or known contraindications should consult a medical professional — institutional protocols typically include medical oversight in distribution plans.
Secure Your KIO3 Supply
Whether you are building a national stockpile, replenishing existing reserves, or evaluating KIO3 for your emergency preparedness programme — Golden Hour Pharma is ready to support your requirements with WHO-GMP certified supply, complete documentation, and dedicated procurement support.